Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2014, with the report issued on March 26, 2014. The filing serves as a regulatory update regarding the European Medicines Agency (EMA) review of GSK's oncology portfolio, specifically concerning the drug Mekinist (trametinib).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory announcement rather than a financial results report.
Material Changes and Regulatory Developments
- Withdrawal of MAA: GSK withdrew its Marketing Authorisation Application (MAA) to the EMA for the combined use of Mekinist (trametinib) and Tafinlar (dabrafenib) for treating adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
- Reason for Withdrawal: The EMA's Committee for Medicinal Products for Human Use (CHMP) indicated that data provided to date did not allow for a conclusion on a positive benefit-risk balance for the combination therapy.
- Monotherapy Status: The application for Mekinist as a single agent in the same patient population remains under review by the EMA.
- Global Approvals: Mekinist remains approved as a single agent and in combination with Tafinlar in the US and Australia, and as monotherapy in Canada.
Outlook, Management Commentary, and Risks
Management Commentary: Dr. Rafael Amado, Head of Oncology R&D, stated that GSK remains committed to providing further data from its ongoing Phase III development programme to support a subsequent re-submission in Europe. The company emphasized the need for more treatment options for metastatic melanoma.
Future Actions: GSK intends to re-submit the MAA for the combined use of Tafinlar and Mekinist when additional data from the ongoing Phase III programme (specifically the COMBI-d study) become available.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the company's 2013 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Verify the timeline for the completion of the Phase III COMBI-d study and the expected date for re-submission to the EMA.
- Confirm the current status of the Mekinist monotherapy application with the EMA.
- Assess the potential impact of the European delay on GSK's oncology revenue projections for the fiscal year.
- Review the specific data points from the Phase II study that led to the CHMP's negative benefit-risk conclusion.